Kojiro Kobayashi

824 total citations · 1 hit paper
56 papers, 544 citations indexed

About

Kojiro Kobayashi is a scholar working on Pulmonary and Respiratory Medicine, Hepatology and Oncology. According to data from OpenAlex, Kojiro Kobayashi has authored 56 papers receiving a total of 544 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 18 papers in Hepatology and 17 papers in Oncology. Recurrent topics in Kojiro Kobayashi's work include Hepatocellular Carcinoma Treatment and Prognosis (13 papers), Gastric Cancer Management and Outcomes (11 papers) and Colorectal Cancer Treatments and Studies (9 papers). Kojiro Kobayashi is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (13 papers), Gastric Cancer Management and Outcomes (11 papers) and Colorectal Cancer Treatments and Studies (9 papers). Kojiro Kobayashi collaborates with scholars based in Japan, United States and Spain. Kojiro Kobayashi's co-authors include Paul Hideo Shingu, Ryosuke O. Suzuki, Takayuki Yoshino, Salvatore Siena, Kanwal Raghav, Maria Di Bartolomeo, Hisato Kawakami, Kensei Yamaguchi, Ikuo Shohji and Élena Elez and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Gut.

In The Last Decade

Kojiro Kobayashi

50 papers receiving 529 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer

2023 96 citations Takayuki Yoshino, Maria Di Bartolomeo et al. Nature Communications profile →

Peers

Countries citing papers authored by Kojiro Kobayashi

Since Specialization

Citations

This map shows the geographic impact of Kojiro Kobayashi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kojiro Kobayashi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kojiro Kobayashi more than expected).

Fields of papers citing papers by Kojiro Kobayashi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kojiro Kobayashi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kojiro Kobayashi. The network helps show where Kojiro Kobayashi may publish in the future.

Co-authorship network of co-authors of Kojiro Kobayashi

This figure shows the co-authorship network connecting the top 25 collaborators of Kojiro Kobayashi. A scholar is included among the top collaborators of Kojiro Kobayashi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kojiro Kobayashi. Kojiro Kobayashi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Adult-onset urea cycle disorder triggered by drug-induced liver injury: A case report 2025 ·Kanzo ·(unknown), Hidenari Nagai, (unknown), (unknown), Kojiro Kobayashi, (unknown), (unknown), (unknown), (unknown), (unknown), Noritaka Wakui, (unknown), (unknown)	0
2	Cross-sectional Study and Comparison between Japan and the United States on Special Regulatory Pathways for Expedited Drug Development and Approval 2025 ·Therapeutic Innovation & Regulatory Science ·Kojiro Kobayashi, (unknown), Mitsuhiro Hashimoto, Hideki Maeda	0
3	HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01 2024 ·Nature Communications ·Salvatore Siena, Kanwal Raghav, Toshiki Masuishi, Kensei Yamaguchi, Tomohiro Nishina, Élena Elez, Javier Rodríguez, Ian Chau, Maria Di Bartolomeo, Hisato Kawakami, Fumitaka Suto, (unknown), Koichiro Inaki, (unknown), (unknown), Daniel Barrios, Kojiro Kobayashi, Axel Grothey, Takayuki Yoshino	15
4	The Usefulness of Serum Interleukin-6 as a Predictor of Response to Atezolizumab plus Bevacizumab Combination Treatment in Hepatocellular Carcinoma 2024 ·Oncology ·(unknown), Hidenari Nagai, (unknown), (unknown), (unknown), Kojiro Kobayashi, (unknown), (unknown), (unknown), Noritaka Wakui, (unknown), Koji Higai, (unknown), Yoshinori Igarashi	1
5	Effects of Lenvatinib on Skeletal Muscle Volume and Cardiac Function in Patients with Hepatocellular Carcinoma 2023 ·Oncology ·Hidenari Nagai, Makoto Amanuma, (unknown), Kojiro Kobayashi, (unknown), (unknown), Go Watanabe, (unknown), (unknown), (unknown), (unknown), (unknown), Noritaka Wakui, (unknown), Koji Higai, (unknown), Yoshinori Igarashi	2
6	Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study. 2023 ·Journal of Clinical Oncology ·Kanwal Raghav, Salvatore Siena, Atsuo Takashima, Takeshi Kato, Marc Van den Eynde, Maria Di Bartolomeo, Yoshito Komatsu, Hisato Kawakami, Marc Peeters, Thierry André, Sara Lonardi, Kensei Yamaguchi, Jeanne Tie, (unknown), John H. Strickler, Daniel Barrios, Qi Yan, Takahiro Kamio, Kojiro Kobayashi, Takayuki Yoshino	43
7	Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer breakdown → 2023 ·Nature Communications ·Takayuki Yoshino, Maria Di Bartolomeo, Kanwal Raghav, Toshiki Masuishi, Fotios Loupakis, Hisato Kawakami, Kensei Yamaguchi, Tomohiro Nishina, Zev A. Wainberg, Élena Elez, J. Rodríguez, Marwan Fakih, Fortunato Ciardiello, Kapil Saxena, Kojiro Kobayashi, Emarjola Bako, Yasuyuki Okuda, Gerold Meinhardt, Axel Grothey, Salvatore Siena, (unknown), (unknown)	96
8	Lenvatinib Might Induce Activation of Host Immunity in Patients with Hepatocellular Carcinoma 2022 ·Oncology ·Hidenari Nagai, (unknown), Kojiro Kobayashi, (unknown), (unknown), (unknown), Go Watanabe, Makoto Amanuma, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Noritaka Wakui, (unknown), Koji Higai, (unknown)	5
9	Usefulness of partial splenic embolization for left-sided portal hypertension in a patient with a pancreatic neuroendocrine neoplasm: a case report and review of the literature 2022 ·Clinical Journal of Gastroenterology ·(unknown), Hidenari Nagai, Makoto Amanuma, Kojiro Kobayashi, (unknown), (unknown), Noritaka Wakui, Naoki Okano, Yoshinori Kikuchi, (unknown), Yoshinori Igarashi	5
10	386O Exploratory biomarker analysis of DESTINY-CRC01, a phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd, DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC) 2021 ·Annals of Oncology ·Salvatore Siena, Kanwal Raghav, Toshiki Masuishi, Kensei Yamaguchi, Tomohiro Nishina, Élena Elez, J. Rodríguez, Ian Chau, Maria Di Bartolomeo, Hisato Kawakami, Fumitaka Suto, Kojiro Kobayashi, (unknown), Koichiro Inaki, Yusuke Kuwahara, (unknown), Axel Grothey, Takayuki Yoshino	20
11	Tivantinib Decreases Hepatocyte Growth Factor-Induced BCRP Expression in Hepatocellular Carcinoma HepG2 Cells 2020 ·Biological and Pharmaceutical Bulletin ·Kojiro Kobayashi, Koji Higai, (unknown), (unknown), Makoto Amanuma, (unknown), (unknown), (unknown), Noritaka Wakui, (unknown), (unknown), (unknown), Hidenari Nagai, Yoshinori Igarashi	5
12	Influence of Sorafenib on Host Immunity in Patients with Liver Cirrhosis With Advanced Hepatocellular Carcinoma Stratified by Etiology 2019 ·Anticancer Research ·Hidenari Nagai, (unknown), Kojiro Kobayashi, Makoto Amanuma, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Noritaka Wakui, (unknown), (unknown), Koji Higai, Yoshinori Igarashi	6
13	Flash Imaging Used in the Post-vascular Phase of Contrast-Enhanced Ultrasonography is Useful for Assessing the Progression in Patients with Hepatitis C Virus-Related Liver Disease 2019 ·Ultrasound in Medicine & Biology ·Noritaka Wakui, Hidenari Nagai, (unknown), Makoto Amanuma, Kojiro Kobayashi, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Kenichi Maruyama, Yasukiyo Sumino, Yoshinori Igarashi	5
14	Hepatic arterialization can predict the development of collateral veins in patients with HCV-related liver disease 2018 ·Journal of Ultrasound ·Noritaka Wakui, Hidenari Nagai, (unknown), Kojiro Kobayashi, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Kenichi Maruyama, Yasukiyo Sumino, Yoshinori Igarashi	4
15	Evaluation of contrast-enhanced ultrasonography for hepatocellular carcinoma prior to and following stereotactic body radiation therapy using the CyberKnife® system: A preliminary report 2015 ·Oncology Letters ·Kazue Shiozawa, Manabu Watanabe, (unknown), Kojiro Kobayashi, (unknown), Yuta Suzuki, (unknown), (unknown), (unknown), Yusuke Okubo, (unknown), (unknown), Nobuhiro Tsukamoto, Yoshinori Igarashi, Yasukiyo Sumino	6
16	Cyberknife, stereotactic body radiation therapy for hepatocellular carcinoma 2014 ·Kanzo ·(unknown), (unknown), (unknown), Kojiro Kobayashi, (unknown), (unknown), (unknown), (unknown), Kazue Shiozawa, (unknown), (unknown)	0
17	Arrival time parametric imaging of the hemodynamic balance changes between the hepatic artery and the portal vein during deep inspiration, using Sonazoid-enhanced ultrasonography: A case of Budd-Chiari syndrome 2013 ·Experimental and Therapeutic Medicine ·Noritaka Wakui, (unknown), (unknown), Naohisa Kamiyama, Kojiro Kobayashi, (unknown), Shigeru Nakano, (unknown), Hidenari Nagai, Yoshinori Igarashi, Yasukiyo Sumino	2
18	Changes of cytokines in patients with liver cirrhosis and advanced hepatocellular carcinoma treated by sorafenib 2013 ·Cancer Chemotherapy and Pharmacology ·Hidenari Nagai, (unknown), Kojiro Kobayashi, (unknown), (unknown), (unknown), Masahiro Kanayama, Noritaka Wakui, (unknown), (unknown), Koji Ishii, Yoshinori Igarashi, Yasukiyo Sumino	9
19	Arrival time parametric imaging using Sonazoid-enhanced ultrasonography is useful for the detection of spoke-wheel patterns of focal nodular hyperplasia smaller than 3 cm 2013 ·Experimental and Therapeutic Medicine ·Noritaka Wakui, (unknown), Naohisa Kamiyama, Kojiro Kobayashi, (unknown), (unknown), (unknown), (unknown), Koji Ishii, Yasukiyo Sumino	10
20	Resistivity and size factor of Al-Si cast alloys according to empirical Matthiessen equation. 1991 ·Journal of Japan Institute of Light Metals ·Shin-ya Komatsu, (unknown), (unknown), Kojiro Kobayashi	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact